Novel DNA topoisomerase I inhibitor. Unlike camptothecin, β-lapachone does not stabilize the cleavable complex, indicating a novel mode of action. Induces apoptosis in HL-60 and human prostate cancer cells via a p53-independent mechanism and blocks the cell cycle at G0/G1.
Product Details
| Formula: | C15H14O3 |
| |
| MW: | 242.27 |
| |
| CAS: | 4707-32-8 |
| |
| Purity: | ≥98% (HPLC) |
| |
| Identity: | Determined by NMR. |
| |
| Appearance: | Orange to brown solid. |
| |
| Solubility: | Soluble in DMSO (25mg/ml) or ethanol (20mg/ml). |
| |
| Shipping: | Ambient Temperature |
| |
| Long Term Storage: | -20°C |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
NAD(P)H:Quinone oxidoreductase activity is the principal determinant of beta-lapachone cytotoxicity: J.J. Pink, et al.; J. Biol. Chem.
275, 5416 (2000),
Abstract;
Full Text
Beta-lapachone-mediated apoptosis in human promyelocytic leukemia (HL-60) and human prostate cancer cells: a p53-independent response: S.M. Planchon, et al.; Cancer Res.
55, 3706 (1995),
Abstract;
Full Text
beta-Lapachone, a novel DNA topoisomerase I inhibitor with a mode of action different from camptothecin: C.J. Li, et al.; J. Biol. Chem.
268, 22463 (1993),
Abstract;
Full Text
